Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis

Kenneth W. Schroeder, William J. Tremaine, Duane M. Ilstrup · New England Journal of Medicine · 1987 · 3K citations

Medicine, Internal Medicine, Pharmacotherapy +14

Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

E. Jan Irvine, Brian G. Feagan, James Rochon et al. · Gastroenterology · 1994 · 720 citations

Pharmacy, Internal Medicine, Inflammation +10

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 446 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus et al. · The Lancet · 2021 · 437 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions

Ivan S. F. Chan, Zhongxin Zhang · Biometrics · 1999 · 290 citations

Public Health, Internal Medicine, Evidence-based Practice +15